240 related articles for article (PubMed ID: 21443199)
1. Organometallic half-sandwich iridium anticancer complexes.
Liu Z; Habtemariam A; Pizarro AM; Fletcher SA; Kisova A; Vrana O; Salassa L; Bruijnincx PC; Clarkson GJ; Brabec V; Sadler PJ
J Med Chem; 2011 Apr; 54(8):3011-26. PubMed ID: 21443199
[TBL] [Abstract][Full Text] [Related]
2. Contrasting reactivity and cancer cell cytotoxicity of isoelectronic organometallic iridium(III) complexes.
Liu Z; Salassa L; Habtemariam A; Pizarro AM; Clarkson GJ; Sadler PJ
Inorg Chem; 2011 Jun; 50(12):5777-83. PubMed ID: 21618978
[TBL] [Abstract][Full Text] [Related]
3. DFT Investigation of the Mechanism of Action of Organoiridium(III) Complexes As Anticancer Agents.
Ritacco I; Russo N; Sicilia E
Inorg Chem; 2015 Nov; 54(22):10801-10. PubMed ID: 26492153
[TBL] [Abstract][Full Text] [Related]
4. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.
Peacock AF; Parsons S; Sadler PJ
J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668
[TBL] [Abstract][Full Text] [Related]
5. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
[TBL] [Abstract][Full Text] [Related]
6. Half-sandwich iridium N-heterocyclic carbene anticancer complexes.
Wang C; Liu J; Tian Z; Tian M; Tian L; Zhao W; Liu Z
Dalton Trans; 2017 May; 46(21):6870-6883. PubMed ID: 28405646
[TBL] [Abstract][Full Text] [Related]
7. Novel and Versatile Imine-N-Heterocyclic Carbene Half-Sandwich Iridium(III) Complexes as Lysosome-Targeted Anticancer Agents.
Yang Y; Guo L; Tian Z; Gong Y; Zheng H; Zhang S; Xu Z; Ge X; Liu Z
Inorg Chem; 2018 Sep; 57(17):11087-11098. PubMed ID: 30133276
[TBL] [Abstract][Full Text] [Related]
8. Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity.
Peacock AF; Habtemariam A; Moggach SA; Prescimone A; Parsons S; Sadler PJ
Inorg Chem; 2007 May; 46(10):4049-59. PubMed ID: 17441712
[TBL] [Abstract][Full Text] [Related]
9. Contrasting Anticancer Activity of Half-Sandwich Iridium(III) Complexes Bearing Functionally Diverse 2-Phenylpyridine Ligands.
Millett AJ; Habtemariam A; Romero-Canelón I; Clarkson GJ; Sadler PJ
Organometallics; 2015 Jun; 34(11):2683-2694. PubMed ID: 26146437
[TBL] [Abstract][Full Text] [Related]
10. Novel half-sandwich iridium(iii) imino-pyridyl complexes showing remarkable in vitro anticancer activity.
Li J; Guo L; Tian Z; Tian M; Zhang S; Xu K; Qian Y; Liu Z
Dalton Trans; 2017 Nov; 46(44):15520-15534. PubMed ID: 29090698
[TBL] [Abstract][Full Text] [Related]
11. Biological activity of neutral and cationic iridium(III) complexes with κP and κP,κS coordinated Ph₂PCH₂S(O)xPh (x = 0-2) ligands.
Ludwig G; Mijatović S; Ranđelović I; Bulatović M; Miljković D; Maksimović-Ivanić D; Korb M; Lang H; Steinborn D; Kaluđerović GN
Eur J Med Chem; 2013 Nov; 69():216-22. PubMed ID: 24042044
[TBL] [Abstract][Full Text] [Related]
12. Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives.
van Rijt SH; Peacock AF; Johnstone RD; Parsons S; Sadler PJ
Inorg Chem; 2009 Feb; 48(4):1753-62. PubMed ID: 19146436
[TBL] [Abstract][Full Text] [Related]
13. Organometallic Iridium(III) anticancer complexes with new mechanisms of action: NCI-60 screening, mitochondrial targeting, and apoptosis.
Hearn JM; Romero-Canelón I; Qamar B; Liu Z; Hands-Portman I; Sadler PJ
ACS Chem Biol; 2013; 8(6):1335-43. PubMed ID: 23618382
[TBL] [Abstract][Full Text] [Related]
14. Pharmaco-genomic investigations of organo-iridium anticancer complexes reveal novel mechanism of action.
Hearn JM; Hughes GM; Romero-Canelón I; Munro AF; Rubio-Ruiz B; Liu Z; Carragher NO; Sadler PJ
Metallomics; 2018 Jan; 10(1):93-107. PubMed ID: 29131211
[TBL] [Abstract][Full Text] [Related]
15. Luminescent dendritic cyclometalated iridium(III) polypyridine complexes: synthesis, emission behavior, and biological properties.
Zhang KY; Liu HW; Fong TT; Chen XG; Lo KK
Inorg Chem; 2010 Jun; 49(12):5432-43. PubMed ID: 20491455
[TBL] [Abstract][Full Text] [Related]
16. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
17. Triphenylamine-Appended Half-Sandwich Iridium(III) Complexes and Their Biological Applications.
He X; Tian M; Liu X; Tang Y; Shao CF; Gong P; Liu J; Zhang S; Guo L; Liu Z
Chem Asian J; 2018 Jun; 13(11):1500-1509. PubMed ID: 29645357
[TBL] [Abstract][Full Text] [Related]
18. Novel iridium(III) iminopyridine complexes: synthetic, catalytic, and in vitro anticancer activity studies.
Kong D; Tian M; Guo L; Liu X; Zhang S; Song Y; Meng X; Wu S; Zhang L; Liu Z
J Biol Inorg Chem; 2018 Jul; 23(5):819-832. PubMed ID: 29934699
[TBL] [Abstract][Full Text] [Related]
19. Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes.
van Rijt SH; Hebden AJ; Amaresekera T; Deeth RJ; Clarkson GJ; Parsons S; McGowan PC; Sadler PJ
J Med Chem; 2009 Dec; 52(23):7753-64. PubMed ID: 19791745
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships for highly potent half-sandwich organoiridium(III) anticancer complexes with C^N-chelated ligands.
Yang Y; Guo L; Ge X; Shi S; Gong Y; Xu Z; Zheng X; Liu Z
J Inorg Biochem; 2019 Feb; 191():1-7. PubMed ID: 30445339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
